

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No 05-1042-B5; (EX03-087C-US))

In the Application of:)	
)	
Kadyk <i>et al.</i>)	
)	Examiner: Swope, Sheridan
Serial No.: 10/535,445)	
)	Group Art Unit: 1652
Filing Date: October 31, 2006)	
)	Confirmation No. 8801
For: CSNKs as Modifiers of the RAC)	
Pathway and Methods of Use)	

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is filed in response to the restriction requirement mailed on May 13, 2009, in the above-mentioned application. Applicants submit herewith a petition for a five month extension of time and the appropriate fee. It is believed that no further fee is due in connection with this filing. However, if a fee is due the Commissioner is authorized to charge our deposit account 13-2490.

With respect to the restriction requirement, Applicants hereby elect with traverse Group I, claims 1-12, allegedly drawn to a method for identifying a RAC pathway modulating agent, for prosecution on the merits. In addition, Applicants hereby elect with traverse a (B) nucleic acid (D) in cell culture (G) using a RAC+ cell in a (M) nucleic acid expression assay and (N) no additional testing in a RAC deficient model system, for prosecution on the merits. The claims readable thereon are claims 1-12.

If the Examiner has any questions regarding this response, she is invited to call the undersigned attorney.

Respectfully submitted,

Dated: September 14, 2009

/Anita J. Terpstra/

Anita J. Terpstra, Ph.D.
Registration No. 47,132

McDonnell, Boehnen, Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-0001